Business Standard

Dr Reddy's Lab rises 2.3%

Related News

The stock jumped 2.3 per cent to Rs 1,204.55 after the company said Phase-III clinical trial for its anti-diabetic molecule balaglitazone achieved the set parameters.

The company which conducted the study to determine the efficacy and safety of the drug, with Rheoscience — a subsidiary of said, it met its primary endpoint of reducing HbA1c or Glycoslated haemoglobin molecule, which indicates glucose level in blood. Besides, the oral anti-diabetic drug also showed effective results on fasting plasma glucose, oedeman and weight gain & body composition.

Read more on:   
|

Quick Links

 

Market News

Grain Board urged for wheat export boost

Wheat export in April-May last year was $475 mn, which came down to $367 mn in the same period this year

Coffee exports decline 5.4% in Jan-Aug

However, exporters' earnings were up 4% to Rs 3,590 cr on higher unit value realisations

BSE-USE merger gets regulatorynod

Two exchanges had agreed to merge with each other in May this year

Sensex, corp earnings set to double in 4 years: BofA-ML

Says Indian Sensex is the best performing market among major global markets so far this year

Nifty ends above 8,000 for the first time on GDP data

Nifty rallied 1,000 points or 17% from 7,000 in 78 trading sessions since May 12, to surpass the 8,000 mark

Back to Top